Elizabeth Hill
Adult Health · Austell, GANPI 1063162485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$710
- Lilly USA, LLC$703
- Amgen$421
- Insulet Corporation$363
- Xeris Pharmaceuticals, Inc.$231
- Boehringer Ingelheim$231
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $710 |
| Lilly USA, LLC | 38 | $703 |
| Amgen | 27 | $421 |
| Insulet Corporation | 18 | $363 |
| Xeris Pharmaceuticals, Inc. | 11 | $231 |
| Boehringer Ingelheim | 12 | $231 |
| Novartis | 10 | $224 |
| Mannkind Corporation | 10 | $201 |
| Tandem Diabetes Care, Inc. | 9 | $173 |
| Ascendis Pharma Endocrinology Inc | 5 | $172 |
| Medtronic | 6 | $157 |
| Corcept Therapeutics | 7 | $156 |
| Bayer | 7 | $144 |
| Radius Health, Inc. | 3 | $113 |
| AbbVie | 7 | $108 |
| Sanofi-aventis U.S. LLC | 4 | $106 |
| Dexcom, Inc. | 5 | $103 |
| Sequel Med Tech, LLC | 4 | $80 |
| Merck | 4 | $71 |
| Cequr Corporation | 2 | $65 |
| AstraZeneca(2 entities) | 3 | $59 |
| Amneal Pharmaceuticals LLC | 2 | $48 |
| Integra Lifesciences Corporation | 1 | $45 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| IBSA Pharma Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| BETA Bionics, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
How this compares
$4,968 in reported general payments places this provider in the 90th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 378 | $411,083 |
| MounjaroTirzepatide | 154 | $166,522 |
| JardianceEmpagliflozin | 129 | $110,187 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 72 | $94,006 |
| FarxigaDapagliflozin Propanediol | 67 | $68,137 |
| TrulicityDulaglutide | 53 | $56,120 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $53,214 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $50,003 |
| TradjentaLinagliptin | 51 | $37,860 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $29,545 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 103 | $25,202 |
| JanuviaSitagliptin Phosphate | 21 | $24,037 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $22,367 |
| Novolog FlexpenInsulin Aspart | 91 | $22,052 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $17,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $710 | $418,344409 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $703 | $235,688242 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $231 | $157,256197 claims |
| AstraZenecaFarxiga | $59 | $68,13767 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $106 | $29,54519 claims |
| MerckJanuvia | $71 | $24,03721 claims |
| BayerKerendia | $144 | $15,20216 claims |
| AbbVieSynthroid | $108 | $3,84757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 577 adult health providers in Georgia.
Other adult health in Austell
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.